A citation-based method for searching scientific literature

John R Ussher, Daniel J Drucker. Endocr Rev 2012
Times Cited: 365







List of co-cited articles
1092 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
35

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
34

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
31

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
27

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
25

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
22

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
734
22

Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
236
19

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
15


Cardiovascular effects of gliptins.
André J Scheen. Nat Rev Cardiol 2013
120
13

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
829
13

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
398
12


Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Amal K Bose, Mihaela M Mocanu, Richard D Carr, Christian L Brand, Derek M Yellon. Diabetes 2005
453
10

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
759
10

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
10

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
10

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
649
9

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee Zourelias, Carol Stolarski, You-tang Shen, Richard P Shannon. Circulation 2004
389
9

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
9

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
9

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George G Sokos, Lazaros A Nikolaidis, Sunil Mankad, Dariush Elahi, Richard P Shannon. J Card Fail 2006
476
8

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Masayuki Arakawa, Tomoya Mita, Kosuke Azuma, Chie Ebato, Hiromasa Goto, Takashi Nomiyama, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada. Diabetes 2010
355
8

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
401
8

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Kiwon Ban, Kyoung-Han Kim, Chan-Kyung Cho, Meghan Sauvé, Eleftherios P Diamandis, Peter H Backx, Daniel J Drucker, Mansoor Husain. Endocrinology 2010
159
8

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
407
8

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
233
8

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen,[...]. Eur Heart J 2012
380
7

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
7

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
300
7

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
488
7

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
486
7


Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
448
7


Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
6

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.
Tingcun Zhao, Pratik Parikh, Siva Bhashyam, Hakki Bolukoglu, Indu Poornima, You-Tang Shen, Richard P Shannon. J Pharmacol Exp Ther 2006
232
6

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, You-Tang Shen, Richard P Shannon. Am J Physiol Heart Circ Physiol 2005
207
6

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Swenja Kröller-Schön, Maike Knorr, Michael Hausding, Matthias Oelze, Alexandra Schuff, Richard Schell, Stephan Sudowe, Alexander Scholz, Steffen Daub, Susanne Karbach,[...]. Cardiovasc Res 2012
130
6

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar, James McLaren, Søren L Kristensen, David Preiss, John J McMurray. Diabetologia 2016
177
6

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Julio Rosenstock, Nikolaus Marx, Steven E Kahn, Bernard Zinman, John J Kastelein, John M Lachin, Erich Bluhmki, Sanjay Patel, Odd-Erik Johansen, Hans-Jürgen Woerle. Diab Vasc Dis Res 2013
113
6

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
209
6

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Meghan Sauvé, Kiwon Ban, M Abdul Momen, Yu-Qing Zhou, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2010
219
6

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
492
6

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
251
6

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
Nikolaus Marx, Julio Rosenstock, Steven E Kahn, Bernard Zinman, John J Kastelein, John M Lachin, Mark A Espeland, Erich Bluhmki, Michaela Mattheus, Bart Ryckaert,[...]. Diab Vasc Dis Res 2015
150
6


Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Ofri Mosenzon, Gil Leibowitz, Deepak L Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre,[...]. Diabetes Care 2017
141
6

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
Darren K McGuire, Frans Van de Werf, Paul W Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B Green, M Angelyn Bethel, Jan H Cornel, Renato D Lopes, Sigrun Halvorsen,[...]. JAMA Cardiol 2016
145
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.